Table 12

Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or sub-studies of major trials, in diabetic subjects (N = 16,032)

Study (ref.)CVD preventionStatin dose and comparatorRisk reductionRelative risk reductionAbsolute risk reductionLDL cholesterol reduction (%)
4S-DM (211)Simvastatin 20–40 mg vs. placebo85.7 to 43.2%50%42.5%186 to 119 mg/dl (36%)
ASPEN 2° (216)Atorvastatin 10 mg vs. placebo39.5 to 24.5%34%12.7%112 to 79 mg/dl (29%)
HPS-DM (212)Simvastatin 40 mg vs. placebo43.8 to 36.3%17%7.5%123 to 84 mg/dl (31%)
CARE-DM (213)Pravastatin 40 mg vs. placebo40.8 to 35.4%13%5.4%136 to 99 mg/dl (27%)
TNT-DM (214)Atorvastatin 80 mg vs. 10 mg26.3 to 21.6%18%4.7%99 to 77 mg/dl (22%)
HPS-DM (212)Simvastatin 40 mg vs. placebo17.5 to 11.5%34%6.0%124 to 86 mg/dl (31%)
CARDS (234)Atorvastatin 10 mg vs. placebo11.5 to 7.5%35%4.0%118 to 71 mg/dl (40%)
ASPEN 1° (216)Atorvastatin 10 mg vs. placebo9.8 to 7.9%19%1.9%114 to 80 mg/dl (30%)
ASCOT-DM (215)Atorvastatin 10 mg vs. placebo11.1 to 10.2%8%0.9%125 to 82 mg/dl (34%)
  • Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation, results of the statin on 10-year risk of major CVD endpoints (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, PharmD, Oregon Health & Science University, 2007.